Saturday, 18 August 2018
Latest news
Main » Is The Stock Risky? Boston Scientific Corporation (BSX)

Is The Stock Risky? Boston Scientific Corporation (BSX)

14 June 2018

Its down 0.38, from 1.34 in 2017Q4. It dropped, as 42 investors sold BSX shares while 181 reduced holdings. The June 35 call is sitting near the top of the list, and data suggests traders are buying to open positions. California Employees Retirement Sys stated it has 0.11% of its portfolio in Boston Scientific Corporation (NYSE:BSX). Campbell And Co Invest Adviser Lc holds 10,080 shares or 0.23% of its portfolio. Following the sale, the chief financial officer now directly owns 299,644 shares of the company's stock, valued at $8,351,078.28. Cleararc Inc has invested 0.14% in Boston Scientific Corporation (NYSE:BSX). Toronto Dominion Bancorporation owns 741,029 shares. Boston Scientific Corporation's institutional ownership is 93.4%, while its institutional transactions stand at -0.08%. Ing Groep Nv invested in 0.07% or 140,480 shares.

Though it has recently stressed to investors its ability to innovate new technologies, over the years Boston Scientific has grown through acquisitions. Td Asset Management Incorporated accumulated 393,820 shares. Factory Mutual Insur accumulated 0.16% or 550,000 shares. 35C; 16/04/2018 - Boston Scientific: Deal May Lead to New Diagnostic Options for Ovarian Cancer; 25/04/2018 - BOSTON SCIENTIFIC 1Q ADJ EPS 33C, EST.

Since December 29, 2017, it had 0 insider purchases, and 20 selling transactions for $9.49 million activity. Shares for $381,949 were sold by Sorenson John Bradley on Thursday, March 1. $399,865 worth of Boston Scientific Corporation (NYSE:BSX) was sold by Phalen Michael P. 20,015 shares were sold by Thepaut Eric Francis Yves, worth $603,368. Ballinger Kevin J. had sold 42,803 shares worth $1.21 million. Price Michael F reported 277,500 shares. Boston Scientitic acquired the company and its Maple Grove location in 1995 for about $1 billion at a time when angioplasty was a fast-growing med-tech therapy. Butcher Arthur C sold $225,413 worth of Boston Scientific Corporation (NYSE:BSX) on Thursday, May 10. Insiders have sold 178,783 shares of company stock worth $5,144,574 over the last 90 days. Fmr Llc who had been investing in Boston Scientific Corp for a number of months, seems to be less bullish one the $44.09 billion market cap company. The stock was last seen 2.96% higher, reaching at $31.95 on 06/08/2018. About 14.04 million shares traded or 98.82% up from the average. Icon Wealth Partners LLC acquired a new position in shares of Boston Scientific during the fourth quarter worth $117,000. It has underperformed by 1.38% the S&P500. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Boston Scientific by 371.6% in the 4th quarter.

Shares in medical-device maker Boston Scientific shot up almost 10 percent in midday trading Monday after a report that it has received a "takeover approach" by Michigan-based orthopedic device company Stryker Corp. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 3.1%.

EPS Estimate for the next Quarter is 0.34. The medical equipment provider reported $0.33 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.32 by $0.01. Visit MarketWatch.com for more information on this news.

The Wall Street Journal reported the news Monday morning.

Shares of Boston Scientific Corporation (BSX) surged 2.96%, amounting to a gain of $0.92 per share, to finish the regular trading session at $31.95 on Friday 06/08/2018. Therefore 86% are positive. The company was maintained on Friday, February 2 by Jefferies. The earnings growth rate for the next years is an important measure for investors planning to hold onto a stock for several years. ValuEngine lowered shares of Boston Scientific from a "buy" rating to a "hold" rating in a research note on Friday, June 1st. On Wednesday, April 25 the stock rating was maintained by Needham with "Buy". RBC Capital Markets maintained the shares of BSX in report on Thursday, February 1 with "Buy" rating. As per Tuesday, December 12, the company rating was maintained by BMO Capital Markets. The company presently has an average rating of Buy and a consensus price target of $32.39. Kbc Grp Nv reported 0.18% of its portfolio in Boston Scientific Corporation (NYSE:BSX). At the time of writing, Boston Scientific Corporation (NYSE:BSX) has a 14-day Commodity Channel Index (CCI) of 388.52. Piper Jaffray has "Buy" rating and $31.0 target. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapy systems.

Is The Stock Risky? Boston Scientific Corporation (BSX)